Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Revenue of Verrica Pharmaceuticals Inc. (VRCA)
Revenue in 2023 (TTM): $5.12 M
According to Verrica Pharmaceuticals Inc.'s latest financial reports the company's current revenue (TTM) is $5.12 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Verrica Pharmaceuticals Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $5.12 M | $4.38 M | $-62,197,000 | $-66,995,000 | $-66,995,000 |
| 2022 | $9.03 M | $8.31 M | $-21,597,000 | $-24,487,000 | $-27,678,000 |
| 2021 | $12 M | $11.53 M | $-30,313,000 | $-35,080,000 | $-38,903,000 |
| 2020 | $ | $-229,000 | $-39,432,000 | $-42,694,000 | $-45,497,000 |
| 2019 | $ | $-257,199 | $-30,080,000 | $-28,207,000 | $-27,950,000 |
| 2018 | $ | $-20,294 | $-20,627,706 | $-20,648,000 | $-20,648,000 |
| 2017 | $ | $ | $-4,457,000 | $-4,459,000 | $-4,459,000 |
| 2016 | $ | $ | $-1,913,000 | $-1,913,000 | $-1,913,000 |